M. Flowers

发表

Allogeneic marrow transplantation for aplastic anaemia associated with dyskeratosis congenita

H. Deeg, K. Sullivan, S. Crawford, 1996, British journal of haematology.

Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.

K. Sullivan, R. Storb, D. Maloney, 1997, Blood.

Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.

H. Deeg, R. Storb, W. Leisenring, 1997, Blood.

Low‐dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA‐matched related donors in patients with Fanconi anaemia

H. Deeg, R. Storb, W. Leisenring, 2005, British journal of haematology.

Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.

H. Deeg, K. Sullivan, R. Storb, 1999, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease.

R. Storb, P. Mcsweeney, T. Gooley, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia

H. Deeg, R. Storb, F. Appelbaum, 2001, British journal of haematology.

Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.

H. Deeg, K. Sullivan, R. Storb, 1997, Blood.

A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.

H. Deeg, K. Sullivan, J. Nims, 1996, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

J. Sierra, R. Storb, F. Appelbaum, 1998, Annals of the New York Academy of Sciences.

Cyclophosphamide-Based In Vivo T-Cell Depletion for HLA-Haploidentical Transplantation in Fanconi Anemia

H. Deeg, R. Storb, M. Thakar, 2012, Pediatric hematology and oncology.

Use of screening studies to predict survival among patients who do not have chronic graft-versus-host disease at day 100 after bone marrow transplantation.

R. Storb, G. Longton, P. Martin, 2001, Biology of Blood and Marrow Transplantation.

Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

K. Sullivan, F. Appelbaum, C. Anasetti, 1991, Seminars in hematology.

Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers.

H. Deeg, R. Storb, W. Leisenring, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease

R. Storb, M. Flowers, P. Carpenter, 2005, Bone Marrow Transplantation.

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

H. Deeg, K. Sullivan, R. Storb, 1997, Blood.

Long-term transplantation of canine keratinocytes made resistant to G418 through retrovirus-mediated gene transfer.

R. Storb, D. Niederwieser, A. Miller, 1990, Proceedings of the National Academy of Sciences of the United States of America.

The development of chronic graft-versus-host disease: an analysis of screening studies and the impact of corticosteroid use at 100 days after transplantation

J Wagner, K. Sullivan, R. Storb, 1998, Bone Marrow Transplantation.

Recipient-specific donor cytotoxic T lymphocytes enhance engraftment of unrelated, DLA non-identical canine marrow.

F. Appelbaum, D. Niederwieser, I. Schwarzinger, 1994, Bone marrow transplantation.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

J. Radich, J Wagner, R. Storb, 2001, Blood.

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

R Storb, S. Heimfeld, R. Storb, 2001, The New England journal of medicine.

Pathophysiology and treatment of graft-versus-host disease.

K. Sullivan, E. Kansu, M. Flowers, 1999, Hematology/oncology clinics of North America.

Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions.

R. Collins, D. Porter, R. Mick, 2000, Blood.

Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation.

J. Radich, C. Higano, F. Appelbaum, 1997, Blood.

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

R. Storb, D. Maloney, B. Storer, 2001, Blood.

CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation.

S. Heimfeld, R. Storb, J. Zaucha, 2001, Blood.

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

H. Deeg, B. Wood, M. Sorror, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

H. Deeg, P. Hari, M. Sorror, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

H. Deeg, J. Radich, S. Heimfeld, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial.

M. Boeckh, L. Corey, M. Flowers, 2000, Blood.

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

F. M. Stewart, M. Sorror, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

H. Deeg, R. Storb, W. Leisenring, 2002, Blood.

Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.

K. Sullivan, D. Douek, R. Storb, 2001, Blood.

Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens

M. Sorror, R. Storb, B. Sandmaier, 2008, Bone Marrow Transplantation.

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

H. Deeg, B. Wood, R. Storb, 2020, Cancers.

Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation

H. Deeg, J Wagner, K. Sullivan, 2003, Bone Marrow Transplantation.

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.

J Wagner, R. Storb, B. Sandmaier, 2001, Blood.

A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients.

R. Storb, F. Appelbaum, M. Flowers, 1999, Blood.

Thalidomide for treatment of patients with chronic graft-versus-host disease.

H. Deeg, R. Storb, W. Leisenring, 2000, Blood.

Late complications of allogeneic and autologous marrow transplantation.

K. Sullivan, F. Appelbaum, C. Anasetti, 1992, Bone marrow transplantation.

Factors affecting antibody levels after allogeneic hematopoietic cell transplantation.

D. Maloney, B. Storer, M. Boeckh, 2003, Blood.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.

S. Hirschfeld, Stephanie J. Lee, M. Flowers, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.

D. Hockenbery, T. Gooley, G. McDonald, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation

H. Deeg, B. Sandmaier, E. Warren, 2007, Bone Marrow Transplantation.

Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis

D. Blaise, M. Horowitz, M. Flowers, 2016, Bone Marrow Transplantation.

Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation.

R. Storb, F. Appelbaum, G. Schoch, 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors.

H. Deeg, R. Storb, F. Appelbaum, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.

H. Deeg, K. Sullivan, R. Storb, 1992, Bone marrow transplantation.

Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation.

H. Deeg, R. Storb, B. Sandmaier, 2019, Blood.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

H. Deeg, J. Radich, R. Storb, 2003, Blood.

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.

J. Fay, W. Wood, J. Maciejewski, 2018, Leukemia research.

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

B. Clurman, H. Deeg, R. Storb, 2007, Blood.

Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia.

B. Storer, A. Woolfrey, M. Flowers, 2011, Blood.

Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age.

R. Storb, B. Sandmaier, W. Leisenring, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation.

J. Radich, M. Loken, M. Flowers, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.